Literature DB >> 19903771

The association and nuclear translocation of the PIAS3-STAT3 complex is ligand and time dependent.

Snehal Dabir1, Amy Kluge, Afshin Dowlati.   

Abstract

The epidermal growth factor (EGF) receptor activation of downstream signal transducers and activators of transcription 3 (STAT3) plays a crucial role in the pathogenesis of lung cancer. STAT3 transcriptional activity can be negatively regulated by protein inhibitor of activated STAT3 (PIAS3). We investigated the time-dependent PIAS3 shuffling and binding to STAT3 in an EGF-dependent model in lung cancer by using confocal microscopy, immunoprecipitation, luciferase reporter assay, and protein analysis of segregated cellular components. We also explored the role of phosphorylation at Tyr705 of STAT3 in the formation and intracellular shuffling of the PIAS3-STAT3 complex. In a growth factor-free state, PIAS3 was localized to the cytoplasm and unbound to STAT3 in both H520 and A549 cells. On exposure to EGF, we observed STAT3 phosphorylation and rapid formation of the PIAS3-STAT3 complex. Within 5 minutes, there was a progressive translocation of the complex to the nucleus, and by 10 minutes, PIAS3 was uniquely localized to the nuclear compartment. After 30 minutes, PIAS3 returned to the cytoplasm. Using site-directed mutagenesis, we substituted Tyr705 of STAT3 with a phenylalanine. Despite EGF stimulation, we observed a significant decrease in PIAS3-STAT3 binding and a significant reduction in nuclear translocation of PIAS3. Furthermore, there was a significant reduction in the capacity of PIAS3 to reduce STAT3-mediated gene transcription. In wild-type STAT3 cells, increasing concentrations of PIAS3 resulted in a proportional decrease in STAT3 phosphorylation. These data suggest an important role for the negative regulatory effect of PIAS3 on STAT3 in EGF-driven tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903771      PMCID: PMC2783234          DOI: 10.1158/1541-7786.MCR-09-0313

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  24 in total

1.  PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases.

Authors:  Noora Kotaja; Ulla Karvonen; Olli A Jänne; Jorma J Palvimo
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

Review 2.  Transcription factors as targets for cancer therapy.

Authors:  James E Darnell
Journal:  Nat Rev Cancer       Date:  2002-10       Impact factor: 60.716

Review 3.  Stats: transcriptional control and biological impact.

Authors:  David E Levy; J E Darnell
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

4.  Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer.

Authors:  Amy Kluge; Snehal Dabir; Jeffrey Kern; David Nethery; Balazs Halmos; Patrick Ma; Afshin Dowlati
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

5.  PIAS3 induces SUMO-1 modification and transcriptional repression of IRF-1.

Authors:  Koji Nakagawa; Hideyoshi Yokosawa
Journal:  FEBS Lett       Date:  2002-10-23       Impact factor: 4.124

Review 6.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.

Authors:  Ralf Buettner; Linda B Mora; Richard Jove
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

7.  The 'PINIT' motif, of a newly identified conserved domain of the PIAS protein family, is essential for nuclear retention of PIAS3L.

Authors:  D Duval; G Duval; C Kedinger; O Poch; H Boeuf
Journal:  FEBS Lett       Date:  2003-11-06       Impact factor: 4.124

8.  PIAS3 (protein inhibitor of activated STAT-3) modulates the transcriptional activation mediated by the nuclear receptor coactivator TIF2.

Authors:  Ana M Jiménez-Lara; Mattias J S Heine; Hinrich Gronemeyer
Journal:  FEBS Lett       Date:  2002-08-28       Impact factor: 4.124

9.  PIAS proteins promote SUMO-1 conjugation to STAT1.

Authors:  Daniela Ungureanu; Sari Vanhatupa; Noora Kotaja; Jie Yang; Saara Aittomaki; Olli A Jänne; Jorma J Palvimo; Olli Silvennoinen
Journal:  Blood       Date:  2003-07-10       Impact factor: 22.113

10.  Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: implication of small ubiquitin-related modifier 1 modification.

Authors:  Laurent Pascual-Le Tallec; Olivier Kirsh; Marie-Christine Lecomte; Say Viengchareun; Maria-Christina Zennaro; Anne Dejean; Marc Lombès
Journal:  Mol Endocrinol       Date:  2003-09-18
View more
  17 in total

1.  Protein inhibitor of activated STAT3 expression in lung cancer.

Authors:  Amy Kluge; Snehal Dabir; Ilse Vlassenbroeck; Rosana Eisenberg; Afshin Dowlati
Journal:  Mol Oncol       Date:  2011-03-30       Impact factor: 6.603

2.  Identification of STAT3-independent regulatory effects for protein inhibitor of activated STAT3 by binding to novel transcription factors.

Authors:  Snehal Dabir; Amy Kluge; Mohammad A Aziz; Janet A Houghton; Afshin Dowlati
Journal:  Cancer Biol Ther       Date:  2011-07-15       Impact factor: 4.742

3.  CD30 is a potential therapeutic target in malignant mesothelioma.

Authors:  Snehal Dabir; Adam Kresak; Michael Yang; Pingfu Fu; Gary Wildey; Afshin Dowlati
Journal:  Mol Cancer Ther       Date:  2015-01-14       Impact factor: 6.261

4.  PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status.

Authors:  Snehal Dabir; Amy Kluge; Karen McColl; Yu Liu; Minh Lam; Balazs Halmos; Gary Wildey; Afshin Dowlati
Journal:  Int J Cancer       Date:  2013-09-23       Impact factor: 7.396

5.  TNF deficiency dysregulates inflammatory cytokine production, leading to lung pathology and death during respiratory poxvirus infection.

Authors:  Ma Junaliah Tuazon Kels; Esther Ng; Zahrah Al Rumaih; Pratikshya Pandey; Sigrid R Ruuls; Heinrich Korner; Timothy P Newsome; Geeta Chaudhri; Gunasegaran Karupiah
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-22       Impact factor: 11.205

Review 6.  STAT3 and cardiac remodeling.

Authors:  Arash Haghikia; Britta Stapel; Melanie Hoch; Denise Hilfiker-Kleiner
Journal:  Heart Fail Rev       Date:  2011-01       Impact factor: 4.214

7.  Inhibition of glycogen synthase kinase 3 beta (GSK3β) suppresses the progression of esophageal squamous cell carcinoma by modifying STAT3 activity.

Authors:  Shegan Gao; Shuoguo Li; Xiaoxian Duan; Zhen Gu; Zhikun Ma; Xiang Yuan; Xiaoshan Feng; Huizhi Wang
Journal:  Mol Carcinog       Date:  2017-07-04       Impact factor: 4.784

8.  STAT3/PIAS3 Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube.

Authors:  Uksha Saini; Adrian A Suarez; Shan Naidu; John J Wallbillich; Kristin Bixel; Ross A Wanner; Jason Bice; Raleigh D Kladney; Jenny Lester; Beth Y Karlan; Paul J Goodfellow; David E Cohn; Karuppaiyah Selvendiran
Journal:  Cancer Res       Date:  2018-01-16       Impact factor: 12.701

9.  Brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxel.

Authors:  Jong Hyun Lee; Chulwon Kim; Gautam Sethi; Kwang Seok Ahn
Journal:  Oncotarget       Date:  2015-03-20

10.  Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells.

Authors:  Min Ye; Wei Huang; Rui Liu; Yingli Kong; Yang Liu; Xiaole Chen; Jianhua Xu
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.